Abstract: Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. Specific embodiments of the invention include [His.sup.25 ]PTH and [His.sup.25 His.sup.26 Leu.sup.27 ]PTH.
Type:
Grant
Filed:
April 3, 1992
Date of Patent:
January 17, 1995
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Abstract: Human parathyroid hormone is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human parathyroid hormone is also described.
Type:
Grant
Filed:
May 23, 1991
Date of Patent:
May 4, 1993
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Abstract: Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
Type:
Grant
Filed:
March 28, 1991
Date of Patent:
December 8, 1992
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Inventors:
Alain E. Lagarde, Abdulwahid Abdulwajid, Donna Bueschkens, Deanna Byrne
Abstract: The invention relates to a pharmaceutical composition in the form of a gelatin capsules consisting of a filling containing as active ingredient ranitidine or a physiologically acceptable salt thereof surrounded by a gelatin shell. The filling is formulated based on a non-aqueous matrix consisting of at least one fatty acid glyceride and/or mineral oil or paraffin. Preferably the matrix contains at least one surfactant. The matrix is essentially hydrophobic in character but is also sufficiently hydrophilic to permit dispersion and dissolution of the capsule filling in the gastrointenstinal tract.